Earendil Labs Announces Worldwide Exclusive License Agreement With Sanofi

Boston – April 17, 2025 – Cooley advised Earendil Labs, an artificial intelligence (AI)-driven biotech company affiliated with Helixon Therapeutics, in connection with Earendil Labs’ license agreement with Sanofi for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to HXN-1002 and HXN-1003, both utilizing Earendil Labs’ proprietary AI and high-throughput discovery and research platform. Earendil Labs will receive an upfront payment of $125 million and is eligible to receive $1.72 billion in development and commercial milestone payments, including a $50 million near-term payment, as well as tiered royalties on product sales ranging from the high-single to low-double digits.

Lawyers Geoffrey Spolyar, Yiming Liu and Zack Gong led the Cooley team advising Earendil Labs, with support from Shawn Yu, Aaron Pomeroy, Amanda Pacheco, David Burns, Sharon Connaughton and Karen Tsai.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.